Reduced striatal D2 receptor binding in myoclonus-dystonia

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 2, 2009, Pages 269-274

  Beukers, R J ^a   Booij, J ^a   Weisscher, N ^a   Zijlstra, F ^a   Van Amelsvoort, T A M J ^a   Tijssen, M A J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Dystonia; Molecular imaging; Myoclonus; Neurology; Receptor imaging; SPECT

Indexed keywords

DOPAMINE 2 RECEPTOR; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; TECHNETIUM 99M; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; PYRROLIDINE DERIVATIVE;

ADULT; AGED; AGING; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG UPTAKE; DYSTONIA; DYT11 GENE; FEMALE; GENE; GENE MUTATION; HETEROZYGOTE; HUMAN; MALE; MOLECULAR IMAGING; MYOCLONUS; OCCIPITAL LOBE; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; STATISTICAL ANALYSIS; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NEOSTRIATUM; PROTEIN BINDING; SCINTISCANNING;

ADULT; AGED; BENZAMIDES; CASE-CONTROL STUDIES; DYSTONIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; MYOCLONUS; NEOSTRIATUM; OCCIPITAL LOBE; PROTEIN BINDING; PYRROLIDINES; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 58849119487     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0924-9     Document Type: Article

References (39)

1. A Zimprich M Grabowski F Asmus 2001 Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome Nat Genet 29 66 69
2. Klein C. Myoclonus and myoclonus-dystonias. In: Pulst SM, editor. Genetics of movement disorders. Boston: Academic; 2003. p. 449-69.
3. F Asmus T Gasser 2004 Inherited myoclonus-dystonia Adv Neurol 94 113 119
4. A Piras G El Kharroubi S Kozlov 2000 Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilon-sarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast lines Mol Cell Biol 20 3308 3315
5. MC Gerrits EM Foncke R de Haan 2006 Phenotype-genotype correlation in Dutch patients with myoclonus-dystonia Neurology 66 759 761
6. DA Grimes F Han AE Lang P St George-Hyssop DE Rachaco L Bulman 2002 A novel locus for inherited myoclonus dystonia on 18p11 Neurology 59 1183 1186
7. B Schule N Kock M Svetel 2004 Genetic heterogeneity in ten families with myoclonus-dystonia J Neurol Neurosurg Psychiatry 75 1181 1185
8. CD Marsden JA Obeso JJ Zarranz AE Lang 1985 The anatomical basis of symptomatic hemidystonia Brain 108 463 483
9. JA Obeso S Gimenez-Roldan 1988 Clinicopathological correlation in symptomatic dystonia Adv Neurol 50 113 122
10. JL Vitek 2002 Pathophysiology of dystonia: a neuronal model Mov Disord 17 Suppl 3 S49 62
11. F Yokoi MT Dang J Li Y Li 2006 Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon sarcoglycan deficient mice J Biochem 140 141 146
12. XO Breakefield AJ Blood L Yuqing 2008 The pathophysiological basis of dystonias Nat Rev Neurosci 9 222 234
13. CT Esapa A Waite M Locke 2007 SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA Hum Mol Genet 16 327 342
14. 123I]β-CIT Mov Disord 13 319 323
15. 2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation Neurology 64 347 349
16. 2 receptors J Neural Transm 111 59 67
17. J Staedt G Stoppe A Kogler 1995 Nocturnal myoclonus syndrome (periodic limb movements in sleep) related to central dopamine D2-receptor alteration Eur Arch Psychiatry Clin Neurosci 245 8 10
18. M Laruelle A Abi-Dargham CH van Dyck 1995 SPECT imaging of striatal dopamine release after amphetamine challenge J Nucl Med 36 1182 1190
19. RE Burke S Fahn CD Marsden SB Bressman C Moskowitz J Friedman 1985 Validity and reliability of a rating scale for the primary torsion dystonias Neurology 35 73 77
20. SJ Frucht SE Leurgans M Hallett S Fahn 2002 The unified myoclonus rating scale Adv Neurol 89 361 37
21. DC Costa NP Verhoeff ID Cullum 1990 In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans Eur J Nucl Med 16 813 816
22. J Booij P Korn DH Linszen EA van Royen 1997 Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography Eur J Nucl Med 24 674 677
23. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease J Neurol Neurosurg Psychiatry 62 133 140
24. RB Innis VJ Cunningham J Delforge 2007 Consensus nomenclature for in vivo imaging of reversibly binding radioligands J Cereb Blood Flow Metab 27 1533 1539
25. J Booij JB Habraken P Bergmans 1998 Imaging of dopamine transporters with iodine- 123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease J Nucl Med 39 1879 1884
26. M Grabowski A Zimprich B Lorenz-Depiereux 2003 The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted Eur J Hum Genet 11 138 144
27. EMJ Foncke MCF Gerrits F van Ruissen 2006 Distal myoclonus and late onset in a large Dutch family with myoclonus-dystonia Neurology 67 1677 1680
28. F Asmus A Zimprich S Tezenas du Montcel 2002 Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype Ann Neurol 52 489 492
29. Beukers RJ, Foncke EMJ, van der Meer J, et al. Functional magnetic resonance imaging in myoclonus dystonia. Abstract in New Developments in Functional Research for Movement Disorders: Relevance for Clinical Practice. Amsterdam; 2006. p. 27.
30. 2 receptor availability and amphetamine induced dopamine release in unipolar depression Biol Psychiatry 50 313 322
31. 2 receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study Am J Psychiatry 163 1594 1602
32. 2 receptor binding potential in social phobia Am J Psychiatry 157 457 459
33. YK Yang WJ Yao JP McEvoy 2006 Striatal dopamine D2/D3 receptor availability in male smokers Psychiatry Res 146 87 90
34. 2 receptor-mediated neurotransmission in humans Neuropsychopharmacology 32 450 457
35. 2 receptors in unaffected members of alcoholic families: possible protective factors Arch Gen Psychiatry 63 999 1008
36. 2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse Am J Psychiatry 165 4 507 514
37. 2 receptor binding with iodine-123-iodobenzofuran SPECT J Nucl Med 39 1511 1518
38. 2 receptors Nucl Med Commun 19 781 787
39. A Grünewald A Djarmati K Lohmann-Hedrich 2008 Myoclonus-dystonia: significance of large SGCE deletions Hum Mutat 29 331 332